NRXBF (NurExone Biologic) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NurExone Biologic LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NurExone Biologic's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

NurExone Biologic's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.01). It may suggest that NurExone Biologic is progressively becoming more dependent on debt to grow their business.

NurExone Biologic LT-Debt-to-Total-Asset Historical Data

The historical data trend for NurExone Biologic's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic LT-Debt-to-Total-Asset Chart

NurExone Biologic Annual Data

Trend

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.01

NurExone Biologic Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial									-	-	0.01	0.01	0.01

NurExone Biologic LT-Debt-to-Total-Asset Calculation

NurExone Biologic's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.002	/	2.17
	=

NurExone Biologic's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	0.031	/	3.614
	=

NurExone Biologic (OTCPK:NRXBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

NurExone Biologic LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (OTCPK:NRXBF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

J90:Germany NRX:Canada

Address

1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9

Website

https://www.nurexone.com

NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.